Clinical efficacy and optimal dose of ST-630 (falecalcitriol) in secondary hyperparathyroidism in patients undergoing hemodialysis. Late phase II multicenter trial.
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.